MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1212/wnl.0000000000008561

Медицинская библиотека · Neurology · 2019

Three-year follow-up of prospective trial of focused ultrasound thalamotomy for essential tremor.

Halpern Casey H, Santini Veronica, Lipsman Nir, Lozano Andres M, Schwartz Michael L, Shah Binit B, Elias W Jeff, Cosgrove Garth R, Hayes Michael T, McDannold Nathan, Aldrich Christina, Eisenberg Howard M, Gandhi Dheeraj, Taira Takaomi, Gwinn Ryder, Ro Susie, Witt Jennifer, Jung Na Young, Chang Jin Woo, Rosenberg Jarrett, Ghanouni Pejman

СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVE

To test the hypothesis that transcranial magnetic resonance-guided focused ultrasound (tcMRgFUS) thalamotomy is effective, durable, and safe for patients with medication-refractory essential tremor (ET), we assessed clinical outcomes at 3-year follow-up of a controlled multicenter prospective trial.

METHODS

Outcomes were based on the Clinical Rating Scale for Tremor, including hand combined tremor-motor (scale of 0-32), functional disability (scale of 0-32), and postural tremor (scale of 0-4) scores, and total scores from the Quality of Life in Essential Tremor Questionnaire (scale of 0-100). Scores at 36 months were compared with baseline and at 6 months after treatment to assess for efficacy and durability. Adverse events were also reported.

RESULTS

Measured scores remained improved from baseline to 36 months (all p < 0.0001). Range of improvement from baseline was 38%-50% in hand tremor, 43%-56% in disability, 50%-75% in postural tremor, and 27%-42% in quality of life. When compared to scores at 6 months, median scores increased for hand tremor (95% confidence interval [CI] 0-2, p = 0.0098) and disability (95% CI 1-4, p = 0.0001). During the third follow-up year, all previously noted adverse events remained mild or moderate, none worsened, 2 resolved, and no new adverse events occurred.

CONCLUSIONS

Results at 3 years after unilateral tcMRgFUS thalamotomy for ET show continued benefit, and no progressive or delayed complications. Patients may experience mild degradation in some treatment metrics by 3 years, though improvement from baseline remains significant.

CLINICALTRIALSGOV IDENTIFIER: NCT01827904.

CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for patients with severe ET, unilateral tcMRgFUS thalamotomy provides durable benefit after 3 years.

Для цитирования: Halpern Casey H, Santini Veronica, Lipsman Nir, Lozano Andres M, Schwartz Michael L, Shah Binit B, Elias W Jeff, Cosgrove Garth R, Hayes Michael T, McDannold Nathan, Aldrich Christina, Eisenberg Howard M, Gandhi Dheeraj, Taira Takaomi, Gwinn Ryder, Ro Susie, Witt Jennifer, Jung Na Young, Chang Jin Woo, Rosenberg Jarrett, Ghanouni Pejman. Three-year follow-up of prospective trial of focused ultrasound thalamotomy for essential tremor.. Neurology. 2019. DOI: 10.1212/wnl.0000000000008561.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.